OraVerse - Local Anesthesia Reversal Agent

OraVerse is the first and only local anesthesia reversal agent that rapidly and safely brings patients back to normal sensation and function .It reverses the effects of local anesthesia two times faster.
* Rapidly, and safely, restores normal function so patients can speak, smile, and drink normally twice as fast - some returned to normal in as soon as 15 minutes
* Reverses the effects of the most widely used local anesthetics combined with vasoconstrictor
* In a separate pediatric clinical trial with 152 patients aged 4 to 11 years, the time to recovery of normal lip sensation was accelerated by 53 minutes (47%) in the maxilla and 120 minutes (67%) in the mandible compared with control

As the first and only local anesthesia reversal agent, OraVerse allows you to bring patients back to normal sensation and function twice as fast. In fact, in clinical studies, patients were able to:

* Smile, sooner
* Speak, sooner
* Drink normally, sooner
* Minimize drooling, sooner

OraVerse is easy to use

* Simply inject into the same site where the local anesthetic was given using a standard dental syringe and the same administration technique.
* Dose in a 1:1 ratio to local anesthetic

OraVerse (phentolamine mesylate) is a clear, colorless, sterile, nonpyrogenic, isotonic, preservative-free solution. Each 1.8 mL cartridge contains 0.4 mg phentolamine mesylate.OraVerse, produces an alpha-adrenergic block of relatively short duration resulting in vasodilatation when applied to vascular smooth muscle.

Important Safety Information:
Following parenteral use of phentolamine at doses between 5 and 15 times higher than the recommended dose of OraVerse (phentolamine mesylate), myocardial infarction and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia, bradycardia, and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents.